Open AccessBlinatumomab may induce graft versus host leukemia in patients with pre‐B ALL relapsing after hematopoietic stem cell transplant
Author(s) -
Khan Muhammad Waqas,
Gul Zartash
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.604
Subject(s) - blinatumomab , medicine , hematopoietic stem cell transplantation , stem cell , leukemia , transplantation , immunology , refractory (planetary science) , cancer research , lymphoblastic leukemia , biology , astrobiology , genetics
Key Clinical Message Blinatumomab, a bispecific T‐cell engager monoclonal antibody used to manage Philadelphia chromosome‐negative relapsed or refractory B‐cell precursor acute lymphoblastic leukemia ( ALL ) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell transplantation, a feature which it was post allogeneic bone marrow transplantation, a feature which this drug was not aimed to do.